Warfarin Cilostazol

Drugs that may be affected by proton pump inhibitors include azole antifungal agents (eg, itraconazole, ketoconazole), benzodiazepines, cilostazol, clarithromycin, digoxin, phenytoin, salicylates, sulfonylureas, and warfarin. Drugs that may affect proton pump inhibitors include sucralfate and clarithromycin. 

Drugs that may be affected by itraconazole include alfentanil, almotriptan, alprazolam, amphotericin B, aripiprazole, benzodiazepines, buspirone, busulfan, calcium blockers, carbamazepine, cilostazol, cisapride, corticosteroids, cyclosporine, digoxin, disopyramide, docetaxel, dofetilide, eletriptan, epierenone, ergot alkaloids, haloperidol, HMG-CoA reductase inhibitors, hydantoins (phenytoin), hypoglycemic agents, oral midazolam, phosphodiesterase type 5 inhibitors, pimozide, polyenes, protease inhibitors, quinidine, rifamycins, sirolimus, tacrolimus, tolterodine, triazolam, trimetrexate, vinca alkaloids, warfarin, and zolpidem. 

Clinically important, potentially hazardous interactions with alprazolam, aprepitant, astemizole, atorvastatin, benzodiazepines, carbamazepine, chlordiazepoxide, cilostazol, clonazepam, clorazepate, colchicine, conivaptan, cyclosporine, dabigatran, dasatinib, diazepam, digoxin, dihydroergotamine, disopyramide, ergot alkaloids, fesoterodine, fluoxetine, flurazepam, fluvastatin, HMG-CoA reductase inhibitors, imatinib, ixabepilone, lapatinib, lopinavir, lorazepam, lovastatin, methylprednisolone, methysergide, midazolam, nilotinib, oxazepam, paroxetine, pimozide, pravastatin, prednisone, quazepam, repaglinide, rimonabant, rivaroxaban, sertraline, silodosin, simvastatin, solifenacin, temazepam, temsirolimus, tolvaptan, trabectedin, triazolam, warfarin, zidovudine... 

Cilostazol (Pletal), a selective inhibitor of PDE III, is used for the treatment of intermittent claudication, an occlusive disease of blood vessels in the legs, which causes pain on walking. It acts as a vasodilator and inhibitor of platelet aggregation. Warfarin, initially developed as a rat poison, and a number of similar compounds, are effective anti-clotting agents by their action as vitamin K antagonists. 

Cilostazol does not appear to have a clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Nevertheless, as with other antiplatelet drugs, concurrent use might increase the bleeding risk. 

In a randomised, double-blind, two-way crossover study in 15 healthy subjects, cilostazol 100 mg twice daily for 13 days did not alter the pharmacokinetics of a single 25-mg dose of warfarin given on day 7. Also, prothrombin times, aPTT time and Ivy bleeding time were unaffected. ... 

---

See also in sourсe #XX -- [ ]

---